These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplantation. Russell JA, Brown C, Bowen T, Luider J, Ruether JD, Stewart D, Chaudhry A, Booth K, Jorgenson K, Coppes MJ, Turner AR, Larratt L, Desai S, Poon MC, Klassen J. Bone Marrow Transplant; 1996 May; 17(5):703-8. PubMed ID: 8733685 [Abstract] [Full Text] [Related]
3. Partially mismatched blood cell transplants for high-risk hematologic malignancy. Russell JA, Desai S, Herbut B, Brown C, Luider J, Ruether JD, Stewart D, Chaudhry A, Booth K, Jorgenson K, Coppes MJ, Turner AR, Larratt L, Poon MC, Klassen J. Bone Marrow Transplant; 1997 May; 19(9):861-6. PubMed ID: 9156258 [Abstract] [Full Text] [Related]
4. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation. Glass B, Majolino I, Dreger P, Scimè R, Santoro A, Vasta S, Suttorp M, Haferlach T, Schmitz N. Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054 [Abstract] [Full Text] [Related]
7. Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome. Russell JA, Larratt L, Brown C, Turner AR, Chaudhry A, Booth K, Woodman RC, Wolff J, Valentine K, Stewart D, Ruether JD, Ruether BA, Klassen J, Jones AR, Gyonyor E, Egeler M, Dunsmore J, Desai S, Coppes MJ, Bowen T, Anderson R, Poon MC. Bone Marrow Transplant; 1999 Dec; 24(11):1177-83. PubMed ID: 10642805 [Abstract] [Full Text] [Related]
8. [Preliminary study of HLA haplotype matched and T-cell undepleted allogeneic bone marrow transplantation for treatment of leukemia]. Ji S, Chen H, Wang H. Zhonghua Xue Ye Xue Za Zhi; 2001 Aug; 22(8):408-10. PubMed ID: 11718090 [Abstract] [Full Text] [Related]
11. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia]. Sun J, Meng FY, Liu QF, Xu D, Xu B, Liu XL. Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060 [Abstract] [Full Text] [Related]
12. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Alessandrino EP, Bernasconi P, Caldera D, Colombo A, Malcovati L, Martinelli G, Bonfichi M, Pagnucco G, Salvaneschi L, Bernasconi C. Bone Marrow Transplant; 1999 Mar; 23(6):607-12. PubMed ID: 10217192 [Abstract] [Full Text] [Related]
17. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)]. Ji SQ, Chen HR, Wang HX, Yan HM, Liu J, Xue M, Zhu L. Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179 [Abstract] [Full Text] [Related]
18. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Ringdén O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E, Reiffers J, Arcese W, Vossen JM, Jouet JP, Cordonnier C, Frassoni F. J Clin Oncol; 2004 Feb 01; 22(3):416-23. PubMed ID: 14691124 [Abstract] [Full Text] [Related]